Overview

Optimizing Recovery in Abdominoplasty

Status:
Suspended
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this study is to evaluate the analgesic efficacy of liposomal bupivacaine in optimizing pain control, minimizing the risk of postoperative nausea and vomiting (PONV), and improving recovery after abdominoplasty. This will be done by comparing intraoperative abdominal wall and incisional injection of bupivacaine to bupivacaine plus liposomal bupivacaine in 46 participants 18 years and older undergoing elective abdominoplasty. This will be studied using pain assessments, validated surveys, medication logs and review of medical records.
Phase:
Phase 4
Details
Lead Sponsor:
University of Wisconsin, Madison
Treatments:
Bupivacaine